viewImmunoPrecise Antibodies Ltd

ImmunoPrecise inks new agreement to use proprietary screening platform in cancer therapy

The new antibody discovery collaboration with Entos Pharmaceuticals will use ImmunoPrecise's B cell Select platform in developing a therapeutic candidate to fight cancer

The B cell Select platform is capable of screening millions of cells to identify diverse antibodies

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) announced Monday that it has begun a new collaboration to develop a therapeutic candidate to combat an undisclosed immuno-oncology target using the biotech company’s proprietary screening platform.

The new antibody discovery collaboration is with Edmonton-based Entos Pharmaceuticals Inc, which develops nucleic acid-based therapies.

The agreement sees the two companies using ImmunoPrecise’s B cell Select platform to aid in discovering new antibodies to use in cancer immunotherapy. B cell Select is capable of screening millions of cells to identify diverse antibodies.

READ: ImmunoPrecise guarantees success rate of its B cell Select Antibody Discovery Platform

According to ImmunoPrecise’s CEO Dr Jennifer Bath, the B cell Select platform has a proven track record of discovering large panels of high-affinity antibodies against a broad range of antibody targets, including difficult membrane proteins.

“Our North American B cell laboratory boasts over one decade of experience with a 94% success rate. This is, in part, why we are very confident in these collaborations, and continue to field requests from such reputable groups," Bath said in a statement.

"We are pleased that Entos Pharmaceuticals, a global leader in next generation nucleic acid-based therapies, considers us to be a trusted partner in antibody discovery."

Entos CEO Dr John Lewis said that its team is committed to developing breakthrough medicines to address pressing clinical unmet needs.

"We have been extremely impressed with IPA's B cell Select platform, which provides an ideal approach to develop therapeutic candidates."

Corporate updates

Victoria-based ImmunoPrecise also announced that its director Andy Nixon has resigned from the board, citing a conflict of interest. Chair James Kuo said that company wished him “every success” in the future.

The company also said that it will apply to the TSX Venture Exchange to extend the expiry date of 875,000 share purchase warrants issued in a June 18, 2018 private placement. The warrants, exercisable at C$1 per share, are being extended for one year to June 18, 2020 subject to the acceptance of the regulators.

Shares in Toronto added around 3% to C$0.67.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 1.32 CAD

Market: TSX-V
Market Cap: $94.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...



ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 04/02/2019

2 min read